PALVINE ALEM: Open Payments
NPI 1780258160 · UPPER MARLBORO, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,401 in 56 payments from 12 companies in 2025. Trend: 2023 $1,565 · 2024 $1,412 · 2025 $1,401
Food & beverage: $1,401
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $265 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $206 |
| Vanda Pharmaceuticals Inc. | 6 | $164 |
| Neurocrine BioSciences, Inc. | 3 | $150 |
| ABBVIE INC. | 8 | $145 |
| Lundbeck LLC | 9 | $144 |
| Otsuka America Pharmaceutical, Inc. | 5 | $136 |
| Alkermes, Inc. | 4 | $91 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
| Luye Pharma (USA) Ltd. | 1 | $24 |
Products named: CAPLYTA, AUSTEDO XR, REXULTI, HETLIOZ, INGREZZA, VRAYLAR, VIVITROL, ABILIFY ASIMTUFII.
Industry payments across MD — which companies pay providers there.
